Article
Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.
Digestive diseases and sciences - 1 Nov 2011
Kanda Tatsuo, Imazeki Fumio, Azemoto Ryosaku, Yonemitsu Yutaka, Mikami Shigeru, Kita Kazuhiko, Takashi Motohide, Sunaga Masahiko, Wu Shuang, Nakamoto Shingo, Tawada Akinobu, Arai Makoto, Kato Keizo, Yoshida Yu, Koma Yoshihiro, Fujiwara Keiichi, Fukai Kenichi, Suzuki Noriaki, Yokosuka Osamu
Abstract excerpt
BACKGROUND: The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks. AIMS: We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment. METHODS: Between 2006 and 2009, among 147 patients with HCV genotype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.